PARIS, France (UPDATED)—Switching the antiplatelet regimen in ACS patients from newer, more potent P2Y12 inhibitors to clopidogrel at 1 month post-PCI may reduce bleeding without increasing the risk ...
Personalized clinical research is gaining momentum as the limitations of population-based studies in guiding individual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback